WE.FOR.YOU

Birgit Jansen

“We want to make your life easier with high-quality products coupled with efficient and reliable services.”

Birgit Jansen

Head Contract Manufacturing Business

About us

As a true global partner, we know how to bring products to market at competitive cost.

Grünenthal PRO offers a unique combination of highly efficient production, with very high standards of quality and service level. We are able to adapt and segment our operation to your needs.

As a family owned company, it is our long term commitment that drives sustainable partnerships with our customers.

Video impressions of our production plants

Bulk production

Impressions of our plant in Italy.

Full service in Italy: Assembly of Nasal Spray Devices

Unit dose nasal spray filling and packaging is one of the special technologies we offer from Italy.

Full service in Latin America

Tour (in Spanish) of our primary manufacturing site for supply of solid, semi-solid and liquid products throughout Latin America (amongst others approved by EMA, ANVISA, INVIMA).

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal Group

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Find out more
Pictures of cover and content page of Grünenthal Report 2024/2025

Grünenthal Report 2024/25

Grünenthal has a clear, bold vision: a World Free of Pain. In 2024, we took big steps forward in developing innovative medicines for patients living with pain worldwide. The latest Grünenthal Report provides information about our key objectives and activities, recent business development highlights, and financial performance.
The full Grünenthal Report is available here.
Grünenthal Responsibility Report 2023

Responsibility Report 2023

Grünenthal’s strategy and culture are closely tied to its deep commitment to conducting business responsibly. We aim to have a net-positive impact on patients, employees, partners, and wider society. Each year, we publish our progress in a detailed and externally audited report – in line with the Global Reporting Initiative (GRI) standards.
Check out our latest Responsibility Report.